FEDERAL COURT OF AUSTRALIA
Pfizer Corp v Commissioner of Patents [2006] FCA 164
PRACTICE AND PROCEDURE – joinder of parties / party to be joined – appeal from decision of Commissioner to rectify Register of patents – party to be joined has no present cause of action – proceedings by party seeking to be joined for rectification in the event that the appeal is successful – no prejudice to applicant – application for joinder supported by Commissioner – matters of law can adequately be dealt with by Commissioner – matters of fact not able to be challenged by Commissioner and can be addressed by party seeking to be joined
Patents Act 1990 (Cth) ss 70, 75, 192,
Federal Court Rules O 6 rr 2, 8, 17
Patent Regulations 1991 (Cth) Reg 10.7Bishop, R v Bridgelands Securities Ltd (1990) 25 FCR 311
H Lundbeck A/S v Commissioner of Patents [2005] FCA 1718
Merck & Co Inc v Arrow Pharmaceuticals Limited [2002] APO 13 (17 April 2002)
Merck & Co Inc v Sankyo Co Ltd (1992) 23 IPR 415News Limited v Australian Rugby Football League Limited (1996) 64 FCR 410
Pegang Mining Co Ltd v Choong Sam [1969] 2 MLJ 52R v Australian Broadcasting Tribunal; ex parte Hardiman (1980) 144 CLR 13
Wellness Pty Ltd v Pro Bio Living Waters Pty Ltd [2003] FCA 1048
PFIZER CORP v COMMISSIONER OF PATENTS
NSD 1955 OF 2005
BENNETT J
1 MARCH 2006
SYDNEY
IN THE FEDERAL COURT OF AUSTRALIA
NEW SOUTH WALES DISTRICT REGISTRY
NSD1955 OF 2005
ON APPEAL FROM THE COMMISSIONER OF PATENTS
BETWEEN:
PFIZER CORP
FIRST APPLICANTPFIZER LTD
SECOND APPLICANTPFIZER INC
THIRD APPLICANTPFIZER RESEARCH & DEVELOPMENT COMPANY N.V/SA
FOURTH APPLICANTAND:
COMMISSIONER OF PATENTS
RESPONDENTJUDGE:
BENNETT J
DATE OF ORDER:
1 MARCH 2006
WHERE MADE:
SYDNEY
THE COURT ORDERS THAT:
1. Spirit Pharmaceuticals Pty Ltd be joined as second respondent.
2. The costs of Spirit’s motion, brought by amended notice of motion filed 20 December 2005, be reserved.
Note: Settlement and entry of orders is dealt with in Order 36 of the Federal Court Rules.
IN THE FEDERAL COURT OF AUSTRALIA
NEW SOUTH WALES DISTRICT REGISTRY
NSD1955 OF 2005
ON APPEAL FROM THE COMMISSIONER OF PATENTS
BETWEEN:
PFIZER CORP
FIRST APPLICANTPFIZER LTD
SECOND APPLICANTPFIZER INC
THIRD APPLICANTPFIZER RESEARCH & DEVELOPMENT COMPANY N.V/SA
FOURTH APPLICANTAND:
COMMISSIONER OF PATENTS
RESPONDENT
JUDGE:
BENNETT J
DATE:
1 MARCH 2006
PLACE:
SYDNEY
REASONS FOR JUDGMENT
In this appeal from a decision of the Commissioner of Patents (by her delegate the Deputy Commissioner of Patents) to amend entries in the Register of Patents, Spirit Pharmaceuticals Pty Ltd (‘Spirit’) seeks to be joined as a respondent pursuant to Order 6 rules 2(a) and (b) and O 6 r 8(1) of the Federal Court Rules (‘the Rules’). In the alternative to the order for joinder, Spirit seeks an order that it be granted leave to intervene in the proceedings pursuant to O 6 r 17 or, alternatively, to appear…
Keep reading for free
Create a free CaseChat account to read Pfizer Corp v Commissioner of Patents and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2006] FCA 164
- Decision Date
CaseChat Overview and Summary
The court considered the role of the Commissioner in appeals and the implications of uncontradicted evidence. It was noted that the Commissioner, in the absence of any opposition, is treated as a party but still has limitations in presenting evidence and submissions. The court also evaluated the effect of Pfizer's success in the appeal without Spirit being joined, potentially leading to further uncertainty and the need for fresh proceedings. This would raise common questions of fact and law that might be considered by a different judge. The court concluded that joining Spirit was necessary to ensure all relevant evidence and submissions were appropriately addressed.
The Federal Court ruled that Spirit Pharmaceuticals Pty Ltd should be joined as the second respondent in the appeal. Additionally, the costs associated with Spirit's motion, as amended and filed on 20 December 2005, were to be reserved for future determination. This decision aimed to ensure that all pertinent evidence and submissions were considered in the appeal, thereby maintaining the integrity and certainty of the patent proceedings.
Orders
Orders of the court
1. Spirit Pharmaceuticals Pty Ltd be joined as second respondent.
2. The costs of Spirit’s motion, brought by amended notice of motion filed 20 December 2005, be reserved.
Background
Background to the litigation
The case originated from a decision of the Commissioner of Patents which Pfizer Corp appealed to the court. Subsequently, Spirit Pharmaceuticals Pty Ltd applied to intervene in the appeal, arguing that the appeal should not proceed without them due to overlapping legal and factual issues. The application to join Spirit as a party was heard by the court, which had to decide on the appropriate procedural steps to take in light of the potential implications for Spirit's own business interests.
Decision
Reasons for decision
1. Whether Spirit Pharmaceuticals Pty Ltd should be joined as a second respondent in the appeal.
2. What orders should be made regarding the costs associated with Spirit's motion to intervene.
Held
1. The Court held that Spirit Pharmaceuticals Pty Ltd should be joined as a second respondent in the appeal.
2. The Court held that the costs of Spirit's motion to intervene, as amended on 20 December 2005, be reserved.
Ratio Decidendi
Legal Principle Established
Established by: BENNETT J
In written submissions, Mr Bezzi submitted that if, as Pfizer contends, no factual issues arise and Spirit is not joined, Pfizer should not be permitted to raise any factual issues at the hearing of the appeal or to amend the notice of appeal. Pfizer has not acceded to that suggested condition. Consideration As a general rule, the Commissioner does not seek to present a substantive argument to support her decision (Merck & Co Inc v Sankyo Co Ltd (1992) 23 IPR 415 at 417; R v Australian Broadcasting Tribunal; ex parte Hardiman (1980) 144 CLR 13 at 35-36). In Merck at 418 Lockhart J considered the role of the Commissioner in an appeal from her decision. In normal circumstances, the Commissioner should be heard fully on questions concerning her powers and procedures but her role should be limited when there are parties in the proceeding pursuing active roles. Where there is no party in opposition to the applicant on the appeal, the Commissioner is deemed a party with the full rights of a party. That does not, however, take into consideration the ability of the Commissioner to present evidence and submissions on all aspects of a matter. Although Spirit was not a party to the proceedings before the Commissioner, it did put submissions in writing and provide additional extrinsic material and send them to the Commissioner. They were not specifically cited in the decision and it is not clear whether or not they were considered. It seems to me that, to the extent that reference is appropriately to be made extrinsic material, Mr Bezzi would be well placed to refer to and to deal with it. The Commissioner referred in her decision to evidence adduced by Pfizer as to the history and practice of listing goods on the ARTG and as to a difference between registered and listed goods. The Commissioner was not in a position in a hearing before the Deputy Commissioner to adduce evidence, whether in support, rebuttal or qualification of Pfizer’s evidence. As there was no other party to those proceedings, the evidence was uncontradicted and unqualified. Mr Bezzi points out that the Commissioner was obliged to accept the evidence in the absence of any contrary evidence or submissions. The Commissioner says that she is not in a position to know whether, for example, the commercial evidence referred to in the decision or relevant to the appeal was able to be challenged. Spirit proposes, if joined, to answer and address this evidence. The effect of the Commissioner’s decision is that the Register will be amended to record the term of the patent as expiring on 14 April 2007. If Spirit were not joined and Pfizer were successful in this appeal, the institution of fresh proceedings, which could, in turn, result in an appeal by either party, could well result in a lack of certainty that would affect Spirit’s decision to launch its own product which falls within the scope of the claims of the patent. It is not in dispute that common questions of fact and law arise in these proceedings and proceedings under s 192 of the Act. The claimed relief of rectification arises out of the same transaction or series of transactions as are the subject of the Commissioner’s decision. It is clear that, if such fresh proceedings were brought, another Judge of the Court would be asked to consider the same questions.